RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+18.38%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$8.67B
AUM Growth
+$8.67B
(+15%)
Cap. Flow
+$213M
Cap. Flow
% of AUM
2.46%
Top 10 Holdings %
Top 10 Hldgs %
55.18%
Holding
87
New
9
Increased
9
Reduced
14
Closed
6
Top Buys
| 1 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$177M |
| 2 |
ARTV
Artiva Biotherapeutics, Inc. Common Stock
ARTV
|
$152M |
| 3 |
Vaxcyte
PCVX
|
$55.5M |
| 4 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$46M |
| 5 |
IDEAYA Biosciences
IDYA
|
$42.7M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$88.9M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$75.5M |
| 3 |
Geron
GERN
|
$63.2M |
| 4 |
Ascendis Pharma
ASND
|
$59.4M |
| 5 |
UroGen Pharma
URGN
|
$51.7M |
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Surrozen
SRZN
$107M
| $3.39M | 0.04% |
282,580
| – | – |
|
77
Metagenomi
MGX
$67.2M
| $2.83M | 0.03% |
1,305,239
-172,510
| -12% | -$374K |
|
78
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $2.33M | 0.03% |
333,333
| – | – |
|
79
AN2 Therapeutics
ANTX
$35.3M
| $2.14M | 0.02% |
1,999,997
-3,551,298
| -64% | -$3.8M |
|
|
RGLS
80
DELISTED
Regulus Therapeutics
RGLS
| $1.2M | 0.01% |
766,834
-5,483,166
| -88% | -$8.61M |
|
81
Scilex Holding
SCLX
$131M
| $241K | ﹤0.01% |
7,462
| – | – |
|
|
CYBN
82
Cybin
CYBN
$142M
| – | – |
-1,158,012
| Closed | -$11.9M |
|
83
MacroGenics
MGNX
$121M
| – | – |
-2,082,021
| Closed | -$8.85M |
|
84
Nurix Therapeutics
NRIX
$723M
| – | – |
-650,000
| Closed | -$13.6M |
|
85
Unicycive Therapeutics
UNCY
$75.8M
| – | – |
-263,220
| Closed | -$1.32M |
|
|
86
UroGen Pharma
URGN
$896M
| – | – |
-3,083,430
| Closed | -$51.7M |
|
|
LBPH
87
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| – | – |
-3,289,119
| Closed | -$88.9M |
|